Delivering Innovative Renal
and Vascular Therapies.
Developing novel, first-in-class pharmaceuticals to address the
medical needs of patients with renal and vascular diseases.
Addressing Vascular Access
Failure in Hemodialysis.
Improving vascular access outcomes would provide a
lasting benefit to hemodialysis patients.
We are a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with renal and vascular diseases. Proteon Therapeutics’ first drug candidate, PRT-201, is a locally-acting recombinant human elastase that fragments elastin fibers in blood vessel walls. PRT-201 has received FDA fast track and orphan drug designation in hemodialysis vascular access indications. Proteon is investigating whether elastase could be used as a treatment to dilate arteries and veins and to reduce neointimal hyperplasia in settings where such effects would result in a medical benefit.
